Pilulka's Market Expansion and Innovation
5.1
KEY FINANCIAL INDICATORS
CZK 1.8bn
Revenues
2020
+13%
Average annual
CZK 2.6bn
Estimated revenues
U
increase '20-'23
2023
+17%
Average annual
increase '23-'26
CZK 4.2bn
Forecasted revenues
2026
CZK 36.5m
EBITDA
CZ+SK 2022
CZK 150.7m
EBITDA
CZ+SK 2026
CZK 156.0m
EBITDA
Pilulka
2026
Historical and forecasted revenues, EBITDA and cash flow of Pilulka
Actuals | Forecast
Average annual growth
+17%
Revenues (CZK billion)
4.5
Average annual growth
+13%
3.0
2.4
1.8
1.5
(1.5)
4.2
600
3.6
3.0
2.6
2.5
400
200
EBITDA and cash flow
(CZK million)
0.0
0
2020
2021
2022
2023
2024
2025
2026
(200)
Revenues - RO online
Revenues other
Revenues - CZ online
Revenues - AT online
Adjusted EBITDA
Revenues - CZ offline
Revenues - HU online
Cash flow
Revenues SK online
Revenues - Plus Care
Note: EBITDA is calculated as revenues net of direct costs and operating expenses. Capital expenditures related to the development of IT systems are
capitalised into intangible assets. The presented financial data are based on the Company's management accounting
Company's revenues growth driven by the
continued strengthening of Pilulka on key
markets, i.e. the Czech Republic and
Slovakia and gradual development of
export markets, i.e. Austria, Hungary and
Romania
EBITDA margins of 2.2-1.5% in the Czech
Republic and Slovakia between 2020 and
2022. Company's EBITDA to turn positive
again after 2023, after expansion markets
roll-out
The presented business plan assumes the
successful completion of the SPO in the
amount of CZK 250m
Franchise pharmacies realized revenues
of CZK 953m in 2022. These revenues are
not included in the Company's consolidated
revenues
19
+pilulkaView entire presentation